New treatment options for multidrug-resistant tuberculosis

Therapeutic Advances in Respiratory Disease

Volumn 6, Issue 5, 2012, Pages 255-268

  Field, Stephen K ^a   Fisher, Dina ^b   Jarand, Julie M ^b   Cowie, Robert L ^b  

^a 3330 Hospital Dr NW   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

benzothiazinones; diarylquinolines; ethylenediamines; multidrug resistance; nitroimidazopyrans; oxazolidinones; pyrroles; tuberculosis

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; BEDAQUILINE; BTZ 043; CAPREOMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; LL 3858; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; OFLOXACIN; OXAZOLIDINONE DERIVATIVE; PHENOTHIAZINE DERIVATIVE; PROTIONAMIDE; PYRAZINAMIDE; PYRROLE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TERIZIDONE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANEMIA; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BACTERIAL LOAD; BACTERICIDAL ACTIVITY; BONE MARROW SUPPRESSION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSGLYCEMIA; GASTROINTESTINAL SYMPTOM; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NEUROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

ANTITUBERCULAR AGENTS; DRUG DESIGN; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH;

EID: 84866488944     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465812452193     Document Type: Review

References (126)

1. Ahmad Z. Peloquin C. Singh R. Derendorf H. Tyagi S. Ginsburg A. (2011) PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother 55: 239–245.
2. Alffenaar J. van der Laan T. Simons S. van der Werf T. van de Kasteele P. de Neeling H. (2011) Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480. Antimicrob Agents Chemother 55: 1287–1289.
3. Amaral L. Boeree M. Gillespie S. Udwadia Z. van Soolingen D. (2010) Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! Int J Antimicrob Agents 35: 524–526.
4. Amaral L. Kristiansen J. (2000) Phenothiazines: an alternative to conventional therapy for the initial management of suspected multidrug resistant tuberculosis. A call for studies. Int J Antimicrob Agents 14: 173–176.
5. Amaral L. Martinds M. Viveiros M. Molnar J. Kristiansen J. (2008) Promising therapy of XDR-TB/MDR-TB with thioridazine an inhibitor of bacterial efflux pumps. Curr Drug Targets 9: 816–819.
6. Andries K. Verhasselt P. Guillemont J. Gohlmann H. Neefs J. Winkler H. (2005) A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307: 223–227.
7. Anger H. Dworkin F. Sharma S. Munsiff S. Nilsen D. Ahuja S. (2010) Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000–06. J Antimicrob Chemother 65: 775–783.
8. Balabanova Y. Radiulyte B. Davidaviciene E. Hooper R. Ignatyeva O. Nikolayevsky V. (2011) Survival of drug resistant tuberculosis patients in Lithuania: retrospective national cohort study. BMJ Open 1: e000351.
9. Bashiri G. Squire C. Moreland N. Baker E. (2008) Crystal structures of F420-dependent glucose-6-phosphate dehydrogenase FGD1 involved in the activation of the anti-tuberculosis drug candidate PA-824 reveal the basis of coenzyme and substrate binding. J Biol Chem 283: 17531–17541.
10. Bressler A. Zimmer S. Gilmore J. Somani J. (2004) Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 4: 528–531.
11. Burman W. (2010) Rip van Winkle wakes up: development of tuberculosis treatment in the 21st century. Clin Infect Dis 50(Suppl. 3): S165's172.
12. Burman W. Goldberg S. Johnson J. Muzanye G. Engle M. Mosher A. (2006) Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 174: 331–338.
13. Caminero J. Sotgiu G. Zumla A. Migliori G. (2010) Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 10: 621–629.
14. Cavusoglu C. Karaca-Derici Y. Bilgic A. (2004) In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoβ mutations. Clin Microbiol Infect 10: 662–665.
15. Chang K. Leung C. Yew W. Lau T. Leung W. Tam C. (2010) Newer fluoroquinolones for treating respiratory tract infection: do they mask tuberculosis? Eur Respir J 35: 606–613.
16. Chen P. Gearhart J. Protopopova M. Einck L. Nacy C. (2006) Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro. J Antimicrob Chemother 58: 332–337.
17. Chiang C. Centis R. Migliori G. (2010) Drug-resistant tuberculosis: past, present and future. Respirology 15: 413–432.
18. Colangeli R. Helb D. Sridharan S. Sun J. Varma-Basil M. Hazbon M. (2005) The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol. Mol Microbiol 55: 1829–1840.
19. Cole S. Riccardi G. (2011) New tuberculosis drugs on the horizon. Curr Opin Micobiol 14: 570–576.
20. Condos R. Hadgiangelis N. Leibert E. Jacquette G. Harkin T. Rom W. (2008) Case series of a linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest 134: 187–192.
21. Devasia R. Blackman A. Gebretsadik T. Griffin M. Shintani A. May C. (2009) Fluoroquinolone resistance in M. tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med 180: 365–370.
22. Dhillon J. Andries K. Phillips P. Mitchison D. (2010) Bacterial activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells. Tuberculosis 90: 301–350.
23. Diacon A. Dawson R. Hanekom M. Narunsky K. Maritz S. Venter A. (2010) Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother 54: 3402–3407.
24. Diacon A. Patientia R. Venter A. van Helden P. Smith P. McIlleron H. (2007) Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrobial Agents Chemother 51: 2994–2996.
25. Diacon A. Pym A. Grobusch M. Patientia R. Rustomjee R. Page-Shipp L. (2009) The diarylquinoline TMC207 for multidrug-resistant tuberculosis. New Engl J Med 360: 2397–2405.
26. Dietze R. Hadad D. McGee B. Molino L. Maciel E. Peloquin C. (2008) Early and extended early bacterial activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med 178: 1180–1185.
27. Donald P. Diacon A. (2008) The early bactericidal activity of anti-tuberculosis drugs: a literature review. Tuberculosis 88(Suppl. 1): S75's83.
28. Falzon D. Jaramillo E. Schunemann H. Arentz M. Bauer M. Bayona J. (2011) WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 38: 516–528.
29. Gagneux S. Burgos M. DeRiemer K. Enciso A. Munoz S. Hopewell P. (2006) Impact of bacterial genetics on the transmission of isoniazid resistant Mycobacterium tuberculosis. PLoS Pathogens 2: e61.
30. Garcia A. Palacios J. Ruiz M. Barluenga J. Aznar F. Caba M. (2010) Strong in vitro activities of two new rifabutin analogues against multidrug-resistant Mycobacterium tuberculosis. Antimicrobiol Agents Chemother 54: 5363–5365.
31. Gillespie S. (2002) Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob Agents Chemother 46: 267–274.
32. Ginsburg A. Laurenzi M. Rouse D. Whitney K. Spigelman M. (2009) Assessment of the effects of the nitroimidazo-oxazine, PA-824, on renal function in healthy subjects. Antimicrob Agents Chemother 53: 3726–3733.
33. Ginsburg A. Hooper N. Parrish N. Dooley K. Dornan S. Booth J. (2003) Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis 37: 1448–1452.
34. Global Alliance for TB Drug Development (2008) SQ109. Tuberculosis 88: 159–161.
35. Green S. Maddo J. Huttenbach E. (2001) Linezolid and reversible myelosuppression. JAMA 285: 1291.
36. Haagsma A. Abdillahi-Ibrahim R. Wagner M. Krab K. Vergauwen K. Guillemont J. (2009) Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob Agents Chemother 53: 1290–1292.
37. Haagsma A. Podasca I. Koul A. Andries K. Guillemont J. Lill H. (2011) Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase. PLoS One 6: e23575.
38. Heifets L. Lindholm-Levy P. Iseman M. (1990) Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. Am Rev Respir Dis 141: 626–630.
39. Hu Y. Coates A. Mitchison D. (2008) Comparison of the sterilizing activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis. Int J Tuberc Lung Dis 12: 69–73.
40. Huitric E. Verhasselt P. Andries K. Hoffner S. (2007) In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 51: 4202–4204.
41. Huitric E. Verhasselt P. Koul A. Andries K. Hoffner S. Andersson D. (2010) Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diaryquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 54: 1022–1028.
42. Hurdle J. Lee R. Budha N. Carson E. Qi J. Scherman M. (2008) A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. J Antimicrob Chemother 62: 1037–1045.
43. Ibrahim M. Andries K. Lounis N. Chaffour A. Truffot-Pernot C. Jarlier V. (2007) Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother 51: 1011–1015.
44. Ibrahim M. Truffot-Pernot C. Andries K. Jarlier V. Veziris N. (2009) Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Am J Respir Crit Care Med 180: 553–557.
45. Jayaram R. Gaonkar S. Kaur P. Suresh B. Mahesh B. Jayashree R. (2003) Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 47: 2118–2124.
46. Jia L. Tomaszewski J. Harahan C. Coward L. Noker P. Gorman G. (2005) Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br J Pharmacol 144: 80–87.
47. Johnson J. Hadad D. Boom W. Daley C. Peloquin C. Eisenach K. (2006) Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuber Lung Dis 10: 605–612.
48. Koh W. Kwon O. Gwak H. Chung J. Cho S. Kim W. (2009) Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 64: 388–391.
49. Koul A. Arnoult E. Lounis N. Guillemont J. Andries K. (2011) The challenge of new drug discovery for tuberculosis. Nature 469: 483–490.
50. Koul A. Dendouga N. Vergauwen K. Molenberghs B. Vranckx L. Willebrords R. (2007) Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol 3: 323–324.
51. Koul A. Vranckx L. Dendouga N. Balemans W. van den Wyngaert I. Vergauwen K. (2008) Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem 283: 25273–25280.
52. Lawn S. Zumla A. (2011) Tuberculosis. Lancet 378: 57–72.
53. Lee J. Lee C. Kim D. Yoon H. Kim J. Lee S. (2011) Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes. Korean J Intern Med 26: 153–159.
54. Lenaerts A. Gruppo V. Marietta K. Johnson C. Driscoll D. Tompkins N. (2005) Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis. Antimicrob Agents Chemother 49: 2294–2301.
55. Lienhardt C. Vernon A. Raviglione M. (2010) New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. Curr Opin Pulm Med 16: 186–193.
56. Liu C. Yang N. Wang Q. Hu Y. Li L. Zhang G. (2011) Risk factors associated with fluoroquinolone-resistant tuberculosis in a Beijing tuberculosis referral hospital. Respirology 16: 918–925.
57. Lounis N. Gevers T. van den Berg J. Andries K. (2008) Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model. Antimicrob Agents Chemother 52: 3568–3572.
58. Ma Z. Lienhardt C. McIlleron H. Nunn A. Wang X. (2010) Global tuberculosis drug development pipeline: the need and the reality. Lancet 375: 2100–2109.
59. Makarov V. Manina G. Mikusova K. Mollman U. Ryabova O. Saint-Joanis B. (2009) Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324: 801–804.
60. Marra F. Marra C. Moadebi S. Shi P. Elwood K. Stark G. (2005) Levofloxacin treatment of active tuberculosis and the risk of adverse events. Chest 128: 1406–1413.
61. Matsumoto M. Hashizume H. Tomishige T. Kawasaki M. Tsubouchi H. Sasaki H. (2006) OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 3: e466.
62. McGee B. Dietze Z. Hadad J. Molino P. Maciel E. Boom W. (2009) Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis. Antimicrobial Agents Chemother 53: 3981–3984.
63. Migliori G. Eker B. Richardson M. Sotgiu G. Zellweger J. Skrahina A. (2009) A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 34: 387–393.
64. Mitchison D. (2000) Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 4: 796–806.
65. Mitchison D. (2005) Shortening the treatment of tuberculosis. Nat Biotechnol 23: 187–188.
66. Mitchison D. Fourie P. (2010) The near future: improving the activity of rifamycins and pyrazinamide. Tuberculosis 90: 177–181.
67. Mitnick C. McGee B. Peloquin C. (2009) Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin Pharmacother 10: 381–401.
68. Moadebi S. Harder C. Fitzgerald M. Elwood K. Marra F. (2007) Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs 67: 2077–2099.
69. Moonan P. Quitugua T. Pogoda J. Woo G. Drewyer G. Sahbazian B. (2011) Does directly observed therapy (DOT) reduce drug resistant tuberculosis? BMC Public Health 11: 19.
70. Mukherjee T. Boshoff H. (2011) Nitroimidazoles for the treatment of TB: past, present, and future. Future Med Chem 3: 1427–1454.
71. Nam H. Koh W. Kwon O. Cho S. Shim T. (2009) Daily half-dose linezolid for the treatment of intractable multi-drug resistant tuberculosis. Int J Antimicrob Agents 33: 92–93.
72. Niemi M. Backman J. Fromm M. Neuronen P. Kivisto K. (2003) Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 42: 819–850.
73. Nikonenko B. Protopopova M. Samala R. Einck L. Nacy C. (2007) Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs. Antimicrob Agents Chemother 51: 1563–1565.
74. Nuermberger E. Mitchison D. (2009) Once-weekly treatment of tuberculosis with the diarylquinoline R207910. A real possibility. Am J Respir Crit Care Med 179: 2–3.
75. Nuermberger E. Rosenthal I. Tyagi S. Williams K. Almeida D. Peloquin C. (2006) Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 50: 2621–2625.
76. Nuermberger E. Spigelman M. Yew W. (2010) Current development and future prospects in chemotherapy of tuberculosis. Respirology 15: 764–778.
77. Nuermberger E. Tyagi S. Tasneen R. Williams K. Almeida D. Rosenthal I. (2008) Powerful bactericidal activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 52: 1522–1524.
78. Onajole O. Govender P. van Helden P. Kruger H. Maguire G. Wiid I. (2010) Synthesis and evaluation of SQ109 analogues as potential anti-tuberculosis candidates. Eur J Med Chem 45: 2075–2079.
79. Onajole O. Sosibo S. Govender P. Govender T. van Helden P. Maguire G. (2011) Novel linear diamine disubstituted polycyclic ‘cage’ derivatives as potential antimycobacterial candidates. Chem Biol Drug Des 78: 1022–1030.
80. Papadopoulou M. Bloomer W. McNeil M. (2007) NLCQ-1 and NLCQ-2, two new agents with activity against dormant Mycobacterium tuberculosis. Int J Antimicrob Agents 29: 724–727.
81. Park I. Hong S. Oh Y. Kim M. Lim C. Lee S. (2006) Efficacy and tolerability of daily half-dose linezolid in patients with intractable multi-drug-resistant tuberculosis. J Antimicrob Chemother 58: 701–704.
82. Petrella S. Cambau E. Chauffour A. Andries K. Jarlier V. Sougakoff W. (2006) Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria. Antimicrob Agents Chemother 50: 2853–2856.
83. Protopopova M. Hanrahan C. Nikonenko B. Samala R. Chen P. Gearhart J. (2005) Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother 56: 968–974.
84. Rao S. Alonso S. Rand L. Dick T. Pethe K. (2008) The protonmotive force is required for ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 105: 11945–11950.
85. Reddy V. Andries L. Nacy C. (2010) In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob Agents Chemother 54: 2840–2846.
86. Rosenthal I. Zhang M. Williams K. Peloquin C. Tyagi S. Vernon A. (2007) Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 4: e344.
87. Ruslami R. Nijland H. Aarnoutse R. Alisjahbana B. Soerto A. Ewalds S. (2006) Evaluation of high- versus standard-dose rifampin in Indonesian patients with pulmonary tuberculosis. Antimicrob Agents Chemother 50: 822–823.
88. Ruslami R. Nijland H. Alisjahbana B. Parwati I. van Crevel R. Aartnoutse R. (2007) Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother 51: 2546–2551.
89. Rustomjee R. Diacon A. Allen J. Venter A. Reddy C. Patientia R. (2008) Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 52: 2831–2835.
90. Schecter G. Scott C. True L. Raftery A. Flood J. Mase S. (2010) Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 50: 49–55.
91. Sharma S. Singh A. (2011) Phenothiazines as anti-tubercular agents: mechanistic insights and clinical implications. Expert Opin Investig Drugs 20: 1665–1676.
92. Shi R. Sugawara I. (2010) Development of new anti-tuberculosis drug candidates. Tohoku J Exp Med 221: 97–106.
93. Shinabarger D. Marotti K. Murray R. Lin A. Melchior E. Swaney S. (1997) Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother 41: 2132–2136.
94. Singh R. Manjunatha U. Boshoff H. Young H. Niyomrattanakit P. Ledwidge R. (2008) PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 322: 1392–1395.
95. Sirgel F. Botha F. Parkin D. Van de Wal B. Schall R. Donald P. (1997) The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 156: 901–905.
96. Slayden R. Barry C. (2000) The genetics and biochemistry of isoniazid resistance in Mycobacterium tuberculosis. Microbes Infect 2: 659–669.
97. Spigelman M. (2007) New tuberculosis therapeutics: a growing pipeline. J Infect Dis 196(Suppl. 1): S28's34.
98. Stover C. Warrener P. VanDevanter D. Sherman D. Arain T. Langhorne M. (2000) A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405: 962–966.
99. Sung J. Garcia-Conteras L. Ver Berkmoes J. Peloquin C. Elbert K. Hickey A. (2009) Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation. Antimicrob Agents Chemother 53: 1338–1343.
100. Takiff H. Guerrero E. (2011) Current prospects for the fluoroquinolones as first-line tuberculosis therapy. Antimicrob Agents Chemother 55: 5421–5429.
101. Tang S. Zhang Q. Zeng L. Sun H. Gu J. Hao X. (2011) Efficacy and safety of linezolid in the treatment of extensively drug-resistant tuberculosis. Jpn J Infect Dis 64: 509–512.
102. Tasneen R. Li S. Peloquin C. Taylor D. Williams K. Andries K. (2011) Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother 55: 5485–5492.
103. Tyagi S. Nuermberger E. Yoshimatsu T. Williams K. Rosenthal I. Lounis N. (2005) Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 49: 2289–2293.
104. Udwadia Z. Amale R. Ajbani K. Rodrigues C. (2012) Totally drug-resistant tuberculosis in India. Clin Infect Dis 54: 579–581.
105. Uzun M. Enturan Z. Ang O. (2002) Investigation of cross-resistance between rifampin and rifabutin in Mycobacterium tuberculosis complex strains. Int J Tuberc Lung Dis 6: 164–165.
106. van den Boogard J. Kibiki G. Kisanga E. Boeree M. Aarnoutse R. (2009) New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother 53: 849–862.
107. van der Werf M. Langendam M. Huitric E. Manissero D. (2012) Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis. Eur Respir J 39: 1511–1519.
108. Van Deun A. Maug A. Salim M. Das P. Sarker M. Daru P. (2010) Short, highly effective, and inexpensive standardized treatment of multi-drug resistant tuberculosis. Am J Respir Crit Care Med 182: 684–692.
109. Van Ingen J. van der Laan T. Amaral L. Dekhuijzen R. Boeree M.J. van Soolingen D. (2009) In-vitro activity of thioridazine against mycobacteria. Int J Antimicrob Agents 34: 190–191.
110. Velayati A. Masjed M. Farnia P. Tabarsi P. Ghanavi J. ZiaZarifi A. (2009) Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 136: 420–425.
111. Vergara F. Henriques M. Candea A. Wardell J. de Souza M. (2009) Antitubercular activity of α,ω-diaminoalkanes, H2N(CH2)nNH2. Biorg Med Chem Lett 19: 4937–4938.
112. Veziris N. Ibrahim M. Lounis N. Andries K. Jarlier V. (2011) Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis. PLos One 6: e17556.
113. von der Lippe B. Sandven P. Brubakk O. (2006) Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)–a report of ten cases. J Infect 52: 92–96.
114. Vora A. (2010) Terizidone. JAPI 58: 267–268.
115. Weiner M. Burman W. Luo C. Peloquin C. Engle M. Goldberg S. (2007) Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother 51: 2861–2866.
116. Williams K. Brickner S. Stover C. Zhu T. Ogden A. Tasneen R. (2009a) Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Am J Respir Crit Care Med 180: 371–376.
117. Williams K. Stover C. Zhu T. Tasneen R. Tyagi S. Grosset J. (2009b) Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother 53: 1314–1319.
118. World Health Organization (2008a) Anti-tuberculosis Drug Resistance in the World. Report No. 4. WHO/IUATLD global project on anti-tuberculous drug resistance surveillance. Geneva. http://whqlibdoc.who.int/hq/2008/WHO_HTM_TB_2008.394_eng.pdf ( accessed 12 June 2012).
119. World Health Organization (2008b) Guidelines for the Programmic Management of Drug-resistant Tuberculosis. Emergency update 2008. Geneva. http://whqlibdoc.who.int/publications/2008/9789241547581_eng.pdf ( accessed 4 June 2012).
120. World Health Organization (2010) Multidrug and Extensively Drug-resistant TB (M/XDR-TB). 2010 Global report on surveillance and response. Geneva. http://www.WHO/HTM/TB/2010.3 ( accessed 12 June 2012).
121. World Health Organization (2011a) Guidelines for the Programmic Management of Drug-resistant Tuberculosis. 2011 update. Geneva. http://whqlibdoc.who.int/publications/2011/9789241501583_eng.pdf ( accessed 4 June 2012).
122. World Health Organization (2011b) Tuberculosis MDR-TB and XDR-TB 2011 progress report. http://www.who.int/tb/challenges/mdr/factsheet_mdr_progress_march2011.pdf ( accessed 12 June 2012).
123. Yew W. Cynamon M. Zhang Y. (2011) Emerging drugs for the treatment of tuberculosis. Expert Opin Emerging Drugs 16: 1–21.
124. Yew W. Leung C. (2008) Management of multi-drug resistant tuberculosis: update 2007. Respirology 13: 21–46.
125. Yoshida S. Suzuki K. Iwamoto T. Tsuyuguchi K. Tomita M. Okada M. (2010) Comparison of rifabutin susceptibility and rpoβ mutations in multi-drug-resistant Mycobacterium tuberculosis strains by DNA sequencing and the line probe assay. J Infect Chemother 16: 360–363.
126. Zhang Y. Yew W. (2009) Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 13: 1320–1330.